Skip links

Publications

MiMedx – Halloween Special: Viceroy evidence more PODs and channel stuffing of deceased doctors.

MiMedx – Halloween Special: Viceroy evidence more PODs and channel stuffing of deceased doctors.

in Tags

Part 14 – Halloween Special Viceroy have discovered legal proceedings against MiMedx vendor RedMed for their alleged role in a kickback scheme and False Claims act violations. In addition to this Redmed’s principal Jeff Hannes is also involved with several other Physician Owned/related Distributors (PODs).

MiMedx – More physician owned distributors; MiMedx may not wish to address its investors but it will have to answer the regulators

MiMedx – More physician owned distributors; MiMedx may not wish to address its investors but it will have to answer the regulators

in Tags

Viceroy is releasing more on illegal Physician-Owned Distributors (PODs) operating in the wound care space within the state of Texas. Our spreadsheet will follow shortly to expose multi-state PODS and conflicted operations. PDF Download Link Given the large proportion of income derived from Texas sales,

MiMedx – Bankruptcy & DOJ/FBI indictments of Physician-Owned Medical Center inconvenienced MiMedx CPM channel stuffing program

MiMedx – Bankruptcy & DOJ/FBI indictments of Physician-Owned Medical Center inconvenienced MiMedx CPM channel stuffing program

in Tags

This report focuses on commercial relationships with currently indicted individuals for fraud with direct trading links with MiMedx and  Physician Owned Distributors (PODs) in Texas with more to come. PDF Download Link In this report, we detail exactly what MiMedx management withheld about its relationship

MiMedx – More whistleblowers come forward with details of MiMedx sales scheme

MiMedx – More whistleblowers come forward with details of MiMedx sales scheme

in Tags

PDF Report Download Link Viceroy has previously published on MiMedx detailing its dubious hiring practices, connections to related party employee-owned distributors, improper government filings and undisclosed SEC investigation. Since publication many former MiMedx employees that are not in legal conflict with MiMedx have reached out

MiMedx – Ex-employees blow the lid on MiMedx sales scheme

MiMedx – Ex-employees blow the lid on MiMedx sales scheme

in Tags

Prior to Viceroy’s publications, we filed a significant data bundle of evidence to the SEC Whistleblower program. We always believe where appropriate in notifying regulators first. We under some may not wish to disclose or communicate with Viceroy, however can contact the SEC directly: https://www.sec.gov/whistleblower.

Important Disclaimer – Please read and acknowledge before continuing

Viceroy Research LLC are an investigative financial research group registered in Delaware, USA.

Our research reports have been prepared for educational purposes only and expresses our opinions. Our reports and any statements made in connection with them are the authors’ opinions, which have been based upon publicly available facts, field research, information, and analysis through our due diligence process, and are not statements of fact. All expressions of opinion are subject to change without notice, and we do not undertake to update or supplement any reports or any of the information, analysis and opinion contained in them. We believe that the publication of our opinions about public companies that we research is in the public interest. We are entitled to our opinions and to the right to express such opinions in a public forum. You can access any information or evidence cited in this report or that we relied on to write this report from information in the public domain.

To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the stocks covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. We have a good-faith belief in everything we write; however, all such information is presented “as is,” without warranty of any kind – whether express or implied.

In no event will we be liable for any direct or indirect trading losses caused by any information available on this report. Think critically about our opinions and do your own research and analysis before making any investment decisions. We are not registered as an investment advisor in any jurisdiction. By downloading, reading or otherwise using our research reports, you agree to do your own research and due diligence before making any investment decision with respect to securities discussed herein, and by doing so, you represent to us that you have sufficient investment sophistication to critically assess the information, analysis and opinions in this report. You should seek the advice of a security professional regarding your stock transactions.

This website, all documents contained herein or any information herein should not be interpreted as an offer, a solicitation of an offer, invitation, marketing of services or products, advertisement, inducement, or representation of any kind, nor as investment advice or a recommendation to buy or sell any investment products or to make any type of investment, or as an opinion on the merits or otherwise of any particular investment or investment strategy.

Any examples or interpretations of investments and investment strategies or trade ideas are intended for illustrative and educational purposes only and are not indicative of the historical or future performance or the chances of success of any particular investment and/or strategy.

You should assume that the authors have a direct or indirect interest/position in all stocks (and/or options, swaps, and other derivative securities related to the stock) and bonds covered herein, and therefore stand to realize monetary gains in the event that the price of either declines.

The authors may continue transacting directly and/or indirectly in the securities of issuers covered herein for an indefinite period and may be long, short, or neutral at any time hereafter regardless of their initial recommendation.